Nusinersen (Spinraza)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nusinersen (Spinraza), 4 mg/mL solution for intrathecal injection. Indication: For the treatment of 5q spinal muscular atrophy (SMA).